Senior PAMI: Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00136929 |
Recruitment Status : Unknown
Verified August 2005 by PAMI Coordinating Center.
Recruitment status was: Active, not recruiting
First Posted : August 29, 2005
Last Update Posted : December 13, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Myocardial Infarction | Drug: Thrombolytic therapy Procedure: Percutaneous coronary intervention (PCI) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 530 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Prospective Randomized Trial of Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly "Senior PAMI" |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 70 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age >= 70
- Clinical symptoms > 30 minutes
- Symptom onset <= 12 hours
- ST segment elevation >= 1 mm in 2 or more leads
Exclusion Criteria:
- Prior thrombolytics
- Cardiogenic shock
- Cerebrovascular accident (CVA)
- Prolonged cardiopulmonary resuscitation (CPR)
- Blood pressure (BP) > 180/100 mm Hg
- Active bleeding
- International Normalized Ratio (INR) > 1.4
- Acetylsalicylic acid [aspirin] (ASA) or heparin allergy
- History of neutropenia, thrombocytopenia, hepatic dysfunction, or renal insufficiency
- Peripheral vascular disease (PVD)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00136929
Principal Investigator: | Felix Zijlstra, M.D. | Ziekenhuis de Weezenlanden |
ClinicalTrials.gov Identifier: | NCT00136929 |
Other Study ID Numbers: |
HIC 1999-225 |
First Posted: | August 29, 2005 Key Record Dates |
Last Update Posted: | December 13, 2005 |
Last Verified: | August 2005 |
AMI MI Acute myocardial infarction (AMI), (MI) |
Myocardial Infarction Infarction Ischemia Pathologic Processes Necrosis Myocardial Ischemia |
Heart Diseases Cardiovascular Diseases Vascular Diseases Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action |